2.

培美曲塞疗效

Response to pemetrexed

Item	Sencond-line	Third-line and beyond	Total
Response
Complete response	0	1 (4.2%)	1 (2.7%)
Partial response	1 (7.7%)	1 (4.2%)	2 (5.4%)
Stable disease	9 (69.2%)	8 (33.3%)	17 (45.9%)
Progressive disease	2 (15.4%)	10 (41.7%)	12 (32.4%)
Disease control	10 (76.9%)	10 (41.7%)	20 (54.1%)
Not evaluable	1 (7.7%)	4 (16.7%)	5 (13.5%)
Progression free survival (range) (month)	11.63 (6.44-16.82)	3.22 (0-7.16)	8.05 (2.04-14.06)
Overall survival (range) (month)	26.35 (14.52-38.18)	17.71 (10.18-25.24)	19.29 (15.67-22.90)